Really? There will always be some I suppose, tbh it sounds like you should sell up yourself Wyn, I have seen this down at 40p, holding/adding while SP has been up and down like a hoes kaks.
I haven't remortgaged the house but I am heavily commited here, slept well at 40p and sleep well now.
I think most know the opportunity here and many will hold through till the conclusion.
Check in here less now but keep up the good work Mr R
Gla
Can anyone explain this 0% response rate?
https://www.fiercebiotech.com/biotech/despite-0-response-rate-4d-hits-primary-endpoint-keytruda-combo-trial-sending-stock-skyward
NDN exactly if big pharma buys us out then its either to sideline Precision for their own needs or to get it all to themselves. Totally irrelevant as we are bought out.
Its a nonsensical argument you make.
Agreed dont panic, its been a bit of a kicking today again, it might be at the low, it might not be quite there but I am sure its not far away.
If the SP was £2 all the way to ph1a results and they were terrible it would be tanked instantly anyway.
If you were intending to hold longer term until AVA6k data then not much has changed, it either works or it doesnt and DE is a big positive for now.
Im still holding at least until ph1a results and if the SP is still low by April I will take advantage to bed and isa £40k worth into our isas.
Crystallising a loss in the F&S account ready for what I hope will be outstanding ph1a data.
If so it will be a godsend for cancer suffers and and not too bad for shareholders pockets either.
I posted here a while ago my brother was recently diagnosed with stage 4 Adenocarcinoma.
I emailed Avacta clinical trials to request info for suitability for the AVA trial.
Neil Bell kindly replied with information and expressed his best wishes.
Unfortunately he was deemed too unwell for any chemo and passed within 3 months at 52 years young.
Just saying but if all you have to worry about is how much money you have, then you are very fortunate.
GLA and hold the nerve.
Yea I seen that earlier Ian, interesting its targeting S1 spike as well.
Also of note it mentions it
"In addition, proof-of-concept work by a separate partner in 2021 demonstrated that the binder can function within an antibody-Optimer pair to enable rapid antigen lateral flow tests. "
Bella, Medusa's Christian Stevenson mentioned to bbc news that they were capable of scaling to 100million per month, think it was early last year.
My expectations for the lft now are low any more than 1-2 million per month would be a bonus for me.
Yes great spot Poirot good man to have on board
Matt was instrumental in identifying and acquiring the PreCision tech from Tufts.
From his linkedin.
Acquisition/ In-licensing deals include the identification and in-licensing the technology used in Avacta’s FAP-activated prodrug pipeline from Tufts Medical School, including the company’s first clinical program AVA6000.
Money means nothing in that situation Cashless.
My brother is only 52 and recently diagnosed with stage 4 adenocarcinoma, a lung cancer.
Hes not in good shape and not healthy enough for chemo.
I pray that Avactas efforts come to a successful conclusion, it will be too late for my bro but hopefully there will be better options for those like him in future.
Best of luck.
Well put RG, so much more than a 'covid stock' like many others I ain't selling a bean until the potential is realized and I truly believe it will, big time.
When this moves it will be like Usain Bolt on steroids.
Regulator you are mistaken.
"If you look at the Medusa 19 web-site (https://www.medusa19.com/en/news/), there's no such notice."
Its on the main page (https://www.medusa19.com/en)
Affiliated to The National Microbiology Framework
We are proud to announce that Medusa 19 has been approved by the NHS Microbiology Framework Lot 1 for Goods and Services, for the supply of SARS-CoV-2 Lateral Flow Tests throughout the UK.
Medusa 19 are one of multiple selected suppliers to this Framework Contract which will run for the next 4 years and has a value of up to £3 Billion.
This Framework Contract allows the provision to all UK Government Departments and Trusts across England, Scotland, Northern Ireland and Wales subject to access agreement signature and Schedule 6 pricing, to supply the Rapid Saliva Protein Test (RSPT) and Avacta’s professional use AffiDx SARS-CoV-2 Antigen Lateral Flow Tests.
The Medusa tests detailed above and other parties lateral flow tests are now available for purchase by various government departments subject to their demand requirements.
Thanks folks just dipped the toe in here finally.
Doubled the days trades so far :)
I have a really good feel about this company, best of luck to all.
I like the look of this daytrade, what broker are you using? as its not available on hl or ii app.
I will try calling them tomorrow and see.